Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck

Next Previous
Trial Profile

Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck

Status: Suspended
Phase of Trial: Phase II/III

Latest Information Update: 03 Aug 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Cetuximab (Primary) ; Cisplatin (Primary) ; Docetaxel (Primary)
  • Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Orofacial cancer; Salivary gland cancer
  • Focus Therapeutic Use

Most Recent Events

  • 03 Aug 2054 NCT04411121 wrongly mentioned as an Obsolete Identifier in NCT01810913 record, hence both CTPs getting attached in same bundle, update accordingly
  • 28 Jul 2026 Status changed from recruiting to suspended.
  • 08 Jul 2021 Planned End Date changed from 1 Jan 2032 to 1 Jan 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top